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In both immunocompromised and immunocompetent patients, Candida and Malassezia are causing or triggering clinical
manifestations such as cutaneous infections and atopic eczema. The innate immune system provides rapid responses to microbial
invaders, without requiring prior stimulation, through a sophisticated system of antimicrobial peptides (AMPs). High molecular
weight kininogen (HMWK) and components of the contact system have previously been reported to bind to Candida and other
pathogens, leading to activation of the contact system. A cutaneous Candida infection is characterized by an accumulation
of neutrophils, leading to an inﬂammatory response and release of enzymatically active substances. In the present study we
demonstrate that antifungal peptide fragments are generated through proteolytic degradation of HMWK. The recombinant
domain 5 (rD5) of HMWK, D5-derived peptides, as well as hydrophobically modiﬁed D5-derived peptides eﬃciently killed
CandidaandMalassezia.Furthermore,theantifungalactivityofmodiﬁedpeptideswasstudiedatphysiologicalconditions.Binding
of a D5-derived peptide, HKH20 (His479-His498), to the fungal cell membrane was visualized by ﬂuorescence microscopy. Our data
disclose a novel antifungal activity of D5-derived peptides and also show that proteolytic cleavage of HMWK results in fragments
exerting antifungal activity. Of therapeutic interest is that structurally modiﬁed peptides show an enhanced antifungal activity.
1.Introduction
The innate immune system provides rapid responses to
microbial invaders without requiring prior stimulation. It
is a sophisticated system comprising epithelial barriers,
white blood cells, various peptides and proteins includ-
ing antimicrobial peptides (AMPs), as well as lipids and
other chemicals, such as reactive oxygen species [1–4].
At present, approximately 1600 AMPs of diﬀerent origin
have been identiﬁed (http://aps.unmc.edu/AP/main.php). A
blend of endogenous AMPs, including the cathelicidin LL-
37/hCAP18, β-defensins, RNase 7, various dermcidins, as
well as psoriasin, are found in skin [5–9]. Peptides of the
histatin family, like many other histidine-rich AMPs [10],
are known to harbor antifungal activities. Histatin 5 is
secreted by the salivary glands and exerts its activity by
entering the fungal cytoplasm targeting the mitochondria
[11, 12]. Bacterial, fungal, and mammalian cell surfaces have
structural diﬀerences which may explain a certain degree
of selectivity for AMP action. Speciﬁcally, bacterial surfaces
contain many anionic components, including LPS and
anionic lipids of Gram-negative bacteria, as well as teichoic
and teichuronic acids of Gram-positive bacteria. Similarly,
glucan, chitin, mannoprotein, and a blend of other cell
wall proteins and polysaccharides contribute to a negative
surface potential of fungal surfaces. Beyond the outer cell
surface, AMPs interact with the plasma membrane. Further-
more, fungal membranes contain mostly zwitterionic lipids
(e.g., phosphatidylcholine), but also ergosterol, whereas
bacterial membranes comprise various acidic phospholipids
(phosphatidylglycerol, phosphatidylserine, and cardiolipin),
which confer a negative charge facilitating AMP binding
and sometimes also defect formation [13–17]. AMPs may
preferentially target fungi, bacteria, or mammalian cells, or
combinations thereof, and the interaction and disruption
of the target membrane is dependent on a number of2 International Journal of Peptides
parameters, including hydrophobic and ionic interactions,
as well as inﬂuence of oligomerisation, the ionic environ-
ment, and the presence of plasma proteins [13–17]. Many
endogenous AMPs are not only antimicrobial, however, but
have many additional functions, including antiendotoxin or
antitumor eﬀects, anti-inﬂammatory properties, mediation
of chemotaxis, or activation of the immune system [7].
Although AMPs display a range of conformations, such as α-
helices and β-sheets, they all share common properties such
as amphipathicity, cationicity, and the propensity to bind
to negatively charged molecules such as negatively charged
phospholipids, glycosaminoglycans, and heparin [18–21].
Concerning bacterial killing, the mechanisms of AMP action
are complex and are often divided into membrane active and
nonmembrane disruptive mechanisms [15, 22, 23].
Candida albicans is normally colonizing human skin as
well as other epithelial surfaces. However, in both immuno-
compromised and immunocompetent patients, Candida
may cause or trigger several clinical manifestations such as
cutaneous infections, atopic eczema, oroesophageal candidi-
asis, candida vaginitis, urinary candidiasis, and disseminated
candidiasis and candidemia [24–26]. C. albicans is the most
prevalent yeast in clinical infections, but non-C. albicans
speciesareincreasinglycausing severeinfectionssuchascan-
didemia, especially in patients suﬀering from endogenous or
drug-induced immunosuppression and critically ill patients
[27]. The yeast Malassezia is a member of the cutaneous
microbialﬂora,andinvolvedinseveraldermatologicdiseases
such as atopic dermatitis, pityriasis versicolor, and sebor-
rheic dermatitis [28], and also reported to cause invasive
infections in premature infants [29]. Importantly, some
Candida isolates are known to have reduced susceptibility
to antifungal drugs [24], which makes other strategies based
on antifungal proteins and peptides interesting alternatives
in the treatment of fungal infections.
Highmolecularweightkininogen(HMWK)andcompo-
nents of the contact system have previously been reported
to have the capacity of binding to the surface of a blend of
human pathogens, including Candida, leading to activation
of the contact system [30–32]. The 120kDa glycoprotein
HMWK contains six domains with diﬀerent functions.
D o m a i n3a n d5h a v eb e e np r e v i o u s l yr e p o r t e dt oh a r b o r
epitopes, that may function as antimicrobial peptides on
release [33, 34]. Furthermore, activation and degrada-
tion of HMWK leads to kallikrein-mediated generation of
bradykinin [35]. However, endogenous generation of active
kinins can also be mediated by the cooperative action of
mast-cell tryptase and neutrophil elastase. Kinins can also be
proteolytically generated from plasma HMWK by the action
of microbial and dust-mite proteases [36, 37].
In the present study, we have investigated whether rD5,
D5-derived peptides, and structurally modiﬁed D5-derived
peptides exert antifungal activity. In addition, the capability
of these modiﬁed peptides to work as antifungal peptides at
physiological conditions was elucidated. Our data disclose
a novel antifungal activity of D5-derived peptides and also
demonstrate that HMWK, when subjected to degradation by
neutrophilic enzymes, may release fragments with antifungal
activity.
2.MaterialsandMethods
2.1. Proteolytic Cleavage of HMWK and Detection of Frag-
ments. To investigate the neutrophil elastase eﬀects on
HMWK, the protein (32μg) was incubated at 37◦Cf o r3 0
and 60minutes with human leukocyte (neutrophil) elastase
(HLE) (24mU) or freeze/thaw-disrupted polymorphonu-
clear neutrophils (PMNs) (18μL, 1×107 cells/mL) in a total
volume of 40μL. HMWK (32μg) incubated at 37◦Cf o r
60minutes was used as a control. TenμL of the material
was analyzed by sodium dodecyl sulphate-polyacrylamide
gel electrophoresis (SDS-PAGE) on a 16.5% Tris-Tricine gel
(Bio-RadLaboratories,Hercules,Calif,USA)underreducing
conditions.
For detection of fragments generated by Cathepsin G,
HMWK (16μg) was incubated with Cathepsin G (9μU)
at 37◦C for 30minutes and analyzed by Western blot
(Figure 1(c)). The proteins were further transferred onto
nitrocellulose membranes (Hybond-C, Amersham Bio-
sciences, UK). The membrane was blocked using 3% (w/v)
skimmed milk (ICN Biomedicals Inc., Ohio, USA), washed,
and then incubated for 1h with rabbit polyclonal antibodies
(Innovagen AB, Lund, Sweden) against the peptide HKH20
(at 1:1500), washed again and incubated with horseradish
peroxidase-conjugated swine antirabbit secondary antibod-
ies (DAKO A/S, Glostrup, Denmark) (1:1000). The pro-
teins reacting with the antibodies were detected by using
enhanced chemiluminescence ECL Western Blotting Detec-
tionReagentsKit(AmershamBiosciences,Buckinghamshire,
UK).
2.2.PeptidesandBiologicalMaterials. Thepeptides(Table 1),
LL-37, histatin 5, and the synthetic peptides HKH20,
GKH17, GGH20, GHG20, GHG21, KHN 20, GKH17WWW,
GKH17WWWWW,andTexasRed-conjugatedHKH20,were
all synthesized by Innovagen AB (Lund, Sweden). The purity
(>95%) and molecular weight of these peptides were conﬁ-
rmed by mass spectral analysis (MALDI-TOF Voyager, App-
lied Biosystems, Foster City, Calif, USA). Citrate plasma
(fresh frozen) from healthy volunteers was obtained from
the blood bank at Sk˚ ane University Hospital, Lund, Sweden.
Neutrophils were prepared by routine procedures (Polymo-
rphprepTM, AXIS-SHIELD PoC AS, Oslo, Norway) from
blood of healthy human donors. The cells were disrupted by
freezethawing followed by the addition of 0.3% Tween 20.
Human leukocyte elastase (4mUμL−1) was obtained from
Calbiochem (San Diego, Calif). The puriﬁcation of recombi-
nantdomain5wasdoneaspreviouslydescribed[33].Brieﬂy,
the expression vector (pET25b) (Novagen, Inc., Madison,
Wis) containing rD5 was expressed in Escherichia coli strain
BL21 (DE3), generously provided by Herwald et al. [38].
E. coli was subjected to induction of protein production by
1mMisopropylthio-β-D-galactoside,and,after3hourincu-
bationat30◦C,thebacteriawereharvestedbycentrifugation.
The pellet was resuspended in sonication buﬀer (50mM
phosphate, 300mM NaCl, pH 8.0), and bacterial cells were
lysedbyrepeatedcyclesoffreezethawing.Thesupernatantof
thelysatewasmixedwith2mLofnickel-nitrilotriacetic acid-
Sepharose (Qiagen GmbH, Hilden, Germany), equilibratedInternational Journal of Peptides 3
Table 1: D5-derived and control peptides investigated.
Peptide Sequence Mw pI1 Net charge Mean hydrophobicity2
KHN20 KHNLGHGHKHERDQGHGHQR 2365.5 9.99 +2 −4.91
GHG20 GHGLGHGHEQQHGLGHGHKF 2127.2 7.21 0 −2.01
GHG21 GHGHKFKLDDDLEHQGGHVLD 2354.5 5.63 −3 −2.32
GGH20 GGHVLDHGHKHKHGHGHGKH 2169.3 9.70 +2 −3.44
HKH20 HKHGHGHGKHKNKGKKNGKH 2151.5 10.78 +7 −5.91
GKH17 GKHKNKGKKNGKHNGWK 1946 10.78 +7 −5.77
GKH17WWW GKHKNKGKKNGKHNGWKWWW 2505 10.78 +7 −3.45
GKH17WWWWW GKHKNKGKKNGKHNGWKWWWWW 2287 10.78 +7 −2.25
LL-37 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES 4492 10.61 +6 −1.84
Histatin-5 DSHAKRHHGYKRKFHEKHHSHRGY 3036 10.28 +5 −4.67
Mw: molecular weight. 1pI: theoretical isoelectric point calculated by using the Protparam tool available at http://us.expasy.org/tools/protparam.html. 2Mean
hydrophobicity calculated using HydroMCalc (combined consensus hydrophobicity scale) available at http://www.bbcm.univ.trieste.it/∼tossi/HydroCalc/
HydroMCalc.html.
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Figure 1: Degradation of HMWK generates antifungal peptides. (a) Intact HMWK and cleavage products from diﬀerent incubations
(indicated below, human leukocyte elastase, HLE, and polymorphonuclear neutrophils, PMN), were analyzed by SDS-PAGE (16.5% Tris-
Tricine gel). (b) Antifungal activity of HMWK cleavage products is shown as clear zones corresponding to inhibition of fungal growth in
RDA. Cleavage of HMWK was performed for 30 and 60minutes at 37◦C. (1) control, buﬀer (10mM Tris, pH 7.4). (2) reference, LL-37
(6μL at 100μM). (3) control, HMWK. (4) control, human leukocyte elastase (HLE). (5) and (6) HMWK incubated with HLE for 30 and 60
minutes, respectively. (7) control, polymorphonuclear neutrophils (PMN). (8) and (9) HMWK incubated with PMN for 30 and 60minutes,
respectively. Data represents the results from a single representative experiment out of three. (c) HMWK was subjected to Cathepsin G,
producing cleavage products recognized by polyclonal antibodies against HKH20 by Western blot analysis. In the panels, molecular mass
markers are indicated on the left.
with sonication buﬀer, and incubated on rotation for 1h
at room temperature. The Sepharose gel was loaded into a
columnwashed,andtherD5proteinwaselutedaspreviously
described [33].
2.3. Determination of Antifungal Activity. C. albicans ATCC
90028 and C. parapsilosis ATCC 90018 were obtained from
the Department of Bacteriology Lund at Sk˚ ane University
Hospital. Cells were precultured overnight on Sabouraud-
dextrose-agar (Difco, Detroit, Mich) at 28◦C, inoculated in
10mL yeast extract-peptone-dextrose (YPD) broth (Sigma-
Aldrich, St. Louis, Mo USA) at 28◦C, and grown to mid-
logarithmic phase. The cells were washed three times and
diluted in 10mM Tris, pH 7.4. FiftyμL of a suspension con-
taining 1 × 106 fungal colony-forming units (cfu)/mL was
incubated at 28◦C for two hours with rD5, HKH20 at con-
centrations ranging from 0.3μMt o6 0μM, or the peptides
HKH20, GKH17, GKH17WWW, and GKH17WWWWW
at a concentration of 30μM. To quantify the fungicidal
activity, serial dilutions of the incubation mixture were4 International Journal of Peptides
plated onto Sabouraud-dextrose-agar plates (Difco, Detroit,
Mich) and incubated for 48h at 28◦C, and the number of
cfu were thereafter determined by counting visible colonies.
Activity of 30μM HKH20, GKH17, GKH17WWW, and
GKH17WWWWW peptides against Candida was also tested
in physiological salt conditions (0.15M NaCl in 10mM Tris,
pH 7.4) in presence of 20% as well as 50% human plasma,
a n d5 0 %h u m a ns e r u m( i n0 . 1 5 MN a C l ,1 0 m MT r i s ,p H
7.4) (Figure 3). The controls (Figure 3) deﬁned the total
(100%) survival of Candida cells incubated in the same
buﬀer under identical conditions but without peptides. To
test the time dependence of fungal killing, Candida was
subjected to 30μM of HKH20 peptide and incubated for 5,
10, 15, 30, 60, and 150minutes (Figure 2(d)).
Radial diﬀusion assay (RDA) was performed as described
byLehreretal.[39]withsomeminormodiﬁcations.Candida
was grown for 16 h at 28◦C in 10mL YPD to obtain yeast
form organisms. The culture was centrifuged at 2000×gf o r
10min then washed three times with 10mM Tris, pH 7.4.
A volume containing 1 × 105 cfu was added to 5mL of
previously autoclaved, 42◦C, underlay agarose gel that con-
tained 1.5mg of Tryptic Soy Broth (TSB) base, 50mg of low-
electroendosmosistype (Low-EEO) agarose type I (A-6013-
25G) (Sigma-Aldrich Inc, St. Louis, Mo, USA), and 1μLo f
Tween 20 (0.02%w/v) (Sigma Chemical Co.) dissolved in
10mM Tris, pH 7.4. The fungi were directly dispensed into
the agar and mixed with a vortex mixer for 10seconds and
thenquicklypouredoutintoapetridish,85mmindiameter.
Wells, 4mm in diameter, were punched, and each well was
then ﬁlled up with 6μL of test sample. After incubation at
35–37◦C for 3h, 5mL of overlay agarose gel, consisting of
300mg TSB, 50mg Low-EEO agarose dissolved in distilled
sterilized water, was poured out on top of the underlay gel.
The clear zone surrounding the wells, indicating antifungal
activity, was measured after 18–24 h of incubation at
28◦C. HMWK degradation products were tested for RDA
inhibitory eﬀects (Figure 1(b)). Human leukocyte (neu-
trophil) elastase (HLE) and freeze-thaw-disrupted polymor-
phonuclear neutrophils (PMNs) at equivalent concentra-
tions as used in the HMWK degradation were incubated at
37◦Cf o r6 0m i n u t e sa n da d d e da sc o n t r o l s( Figure 1(b)).
Malassezia furfur ATCC 44342 (CCUG 24230) was
obtained from the Department of Bacteriology at Sk˚ ane
University Hospital. The antifungal activity was tested in an
assay described by Lopez-Gracia et al. [40], but with some
minor modiﬁcations. Cells were cultured for 2 days at 37oC
in 10mL medium containing 4% Bacto Malt Extract (Bec-
ton, Dickinson and Company, Md, USA), 1% glucose (VWR
international), 1% Tween 80 (Sigma-Aldrich, St. Louis, Mo,
USA)and0.6%BactoPeptone(Becton,DickinsonandCom-
pany, Md, USA). Cells were then washed in 1mM sodium
phosphatebuﬀer,pH7.4.M.furfur cellsweregrowninsterile
96-well microtiter plates (Costar, Corning Incorporated,
Corning, USA) in a total volume of 100μL, containing 60μL
of 1mM sodium phosphate buﬀer, pH 7.4, 20μLo fc u l t u r e
medium, 10μL of a 10x stock solution of the synthetic pep-
tides, and a 10x stock solution of the fungal cell suspension,
resulting in a ﬁnal concentration of 1-2 × 105 cells/mL.
Chloramphenicol was added to each well (16μg/ml) to avoid
contamination. The cells were incubated at 30◦Cf o r2 4h .T o
quantifythefungicidalactivity,serialdilutionsoftheincuba-
tion mixture were plated onto agar plates and incubated 72h
at 37◦C, and the number of cfu thereafter was determined by
countingvisiblecolonies.Theminimalinhibitoryconcentra-
tion(MIC)wasdeﬁnedastheconcentrationwhichyieldedat
least 95% inhibition of fungal growth.
2.4. Fluorescence Microscopy. C. albicans ATCC 90028 was
incubatedfor18hoursin10mLYPD-brothat28◦Ctoobtain
midlogarithmic phase organisms and washed three times,
then diluted in 10mM Tris, pH 7.4, to a concentration of 1×
107 cfu/mL. Two hundred μL of the C. albicans suspension
was incubated for 5min on ice together with 1μLT e x a sR e d -
conjugated HKH20 (2mg/mL). Not only to block binding
of HKH20 to the fungal membrane, but also to exclude
the possibility that the Texas Red-label confers unspeciﬁc
binding to fungal surfaces, 2μL heparin (50mg/mL) was
added to the samples prior to incubation with Texas Red-
conjugated HKH20. The pellets were washed three times in
10mM Tris, pH 7.4. Cell FIX (Becton Dickinson Catalogue
no. 340181) was added (to a ﬁnal concentration of 4%
formaldehyde), and the yeast cell pellets were incubated
15min on ice and then 45min at room temperature. Ethanol
washed glass cover slips were coated with 0.25mL of poly-
lysine (0.2mg/mL dissolved in water), dried, and then
washed with distilled water. The samples were adhered to the
polylysine glasses for 30min and mounted on microscope
slides for visual inspection. A Nikon Eclipse TE300 inverted
ﬂuorescence microscope was used.
2.5. Liposome Preparation and Leakage Assay. The liposomes
investigatedwerezwitterionicDOPC/cholesterol(60/40mol/
mol)orDOPC/ergosterol(60/40mol/mol).DOPC(1,2-Dio-
leoyl-sn-Glycero-3-Phosphatidylcholine) was from Avanti
Polar Lipids (Alabaster, USA) and of >99% purity, while
ergosterol and cholesterol (>99% purity) were from Sigma-
Aldrich (St. Louis, USA). Due to the long, symmetric, and
unsaturated acyl chains of DOPC, several methodological
advantages are reached. In particular, membrane cohesion
is good, which facilitates very stable unilamellar liposomes,
allowing detailed values on leakage to be obtained. The lipid
mixtures were dissolved in chloroform, after which solvent
was removed by evaporation under vacuum overnight.
Subsequently, 10mM Tris buﬀer, pH 7.4, was added together
with 0.1M carboxyﬂuorescein (CF) (Sigma, St. Louis, USA).
After hydration, the lipid mixture was subjected to eight
freeze-thaw cycles consisting of freezing in liquid nitro-
gen and heated to 60◦C. Unilamellar liposomes of about
Ø140 nm were generated by multiple extrusions through
polycarbonate ﬁlters (pore size 100nm) mounted in a
LipoFast miniextruder (Avestin, Ottawa, Canada) at 22◦C.
Untrapped CF was removed by two subsequent gel ﬁltrations
(Sephadex G-50, GE Healthcare, Uppsala, Sweden) at 22◦C,
with Tris buﬀer as eluent. CF release from the liposomes
was determined by monitoring the emitted ﬂuorescence
at 520 nm from a liposome dispersion (10μM lipid in
10mM Tris, 5mM glucose, pH 7.4). An absolute leakage
scale was obtained by disrupting the liposomes at the endInternational Journal of Peptides 5
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Figure 2: Antifungal activity of rD5 and the D5-derived peptide HKH20. (a) In viable count assay, antifungal activities of rD5 and HKH20
were detected. 1 ×106 cfumL−1 of C. parapsilosis ATCC 90018 was incubated in 50μL with rD5 or HKH20 at concentrations ranging from
0.3μMto60μM.(b)C.parapsilosisATCC90018wassubjectedtorD5,HKH20,andthereferencepeptidesLL-37andHistatin-5inRDA,each
well was loaded with 6μl of peptide at the indicated concentrations. (c) The indicated D5-derived peptides (6μL each at 100μM) were tested
in RDA in low salt conditions against C. albicans ATCC 90028. GGH20, HKH20, and GKH17 showed antifungal activity. For comparison,
the reference peptide LL-37 is shown. ∗ indicates a statistically signiﬁcant diﬀerence (P<0.05) in comparison to LL-37. (d) Time-dependent
killing of C. parapsilosis ATCC 90018 by 30μM HKH20 was analyzed by viable count assay. (e) M. furfur ATCC 44342 in a suspension of
1-2 × 105 cells/mL was added to buﬀer only (control, striped) or subjected to 10μM( l i g h tg r a y )o r3 0μM (dark gray) of the AMPs LL-37,
HKH20, or GKH17 and incubated for 24h. (f) M. furfur ATCC 44342 was subjected to increasing concentrations of GKH17 (ﬁlled circle)
and HKH20 (open circle) and incubated for 24h, and the percentage of survived yeast cells is shown. (g) Fluorescence microscopy shows
binding of Texas Red-labeled HKH20 peptide (10μMm L −1)t oCandida cells. Panel 4 shows yeast cells incubated with heparin and Texas
Red-labeled HKH20. Images in panel 2 and 4 were recorded using identical instrument settings. The corresponding Nomarski images are
shown in panels 1 and 3. Data represents the mean of at least duplicate determinations from a single experiment representative of at least
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Figure 3: Antifungal eﬀects of the D5-derived and the modiﬁed peptides. (a)–(e) The D5-derived peptides HKH20, GKH17, and modiﬁed
variants of GKH17 were tested against C. parapsilosis ATCC 90018 in viable count assays at diﬀerent physiological conditions. Candida cells
were subjected to 30 μM of the peptides at (a) low salt conditions (10 mM Tris, pH 7.4), (b) physiological salt conditions (0.15M NaCl in
10mM Tris, pH 7.4), (c) in presence of 20% human plasma (0.15M NaCl, 10mM Tris, pH 7.4), (d) in presence of 50% human plasma
(0.15M NaCl, 10mM Tris, pH 7.4), and (e) in presence of 50% human serum (0.15M NaCl, 10mM Tris, pH 7.4). Most of the antifungal
activities of the D5-derived peptides HKH20 and GKH17 were lost, whereas the activities of the modiﬁed variants of GKH17 peptides were
retained in physiological salt and presence of human plasma or serum. Data represents the mean ± (SD) of triplicate determinations from a
single experiment representative of at least two experiments.
of each experiment through addition of 0.8mM Triton X-
100 (Sigma-Aldrich, St. Louis, USA). A SPEX-ﬂuorolog 1650
0.22-mdoublespectrometer(SPEXIndustries,Edison,USA)
was used for the liposome leakage assay. Measurements were
performed in at least duplicate at 37◦C.
2.6. Statistical Analysis. Comparison of antifungal activity
between the various peptides was performed using Kruskal-
WallisOne-WayAnalysisofVarianceonRanksandpair-ways
multiple-comparison procedures (Tukey Test). P<0.05 was
considered as a signiﬁcant diﬀerence. The statistical software
used was SigmaStat (Systat Software Inc., Point Richmond,
Calif, USA).
3. Results
3.1. Proteolytic Cleavage of HMWK Generates Peptides with
Antifungal Properties. In order to test whether antifungal
peptides could be released after proteolytic digestion of
HMWK in vivo, HMWK was incubated with neutrophil
elastase or extracts of polymorphonuclear neutrophils. Anal-
ysis using SDS-PAGE revealed that HMWK was degraded
into several fragments (Figure 1(a)). Furthermore, when the
fragments were analysed in RDA, antifungal activity was
observed (Figure 1(b)). In analogy to the above, HMWK
incubated with Cathepsin G resulted in the generation of low
molecular-weight fragments corresponding to the previouslyInternational Journal of Peptides 7
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Figure 4: Eﬀects of GKH17 (a) and GKH17WWW (b) on liposome permeability. For both peptides (at the doses indicated),
permeabilization of ergosterol-containing liposomes (open circle) is demonstrated to be higher than that of cholesterol-containing (open
square) ones.
detected 20-mer peptide from D5, HKH20, as assessed by
Western blot using polyclonal antibodies against HKH20
(Figure 1(c)).
3.2. Antifungal Eﬀects of rD5 and the D5-Derived Peptide
HKH20 from HMWK. To investigate whether domain 5 has
antifungal activity, eﬀects of puriﬁed rD5 on C. parapsilosis
ATCC90018weretestedinafungicidalassay(concentrations
ranging from 0.3μMt o6 0 μM) and in RDA. The results
showed a dose-dependent killing of Candida (Figure 2(a)),
and, notably, rD5 exerted inhibitory activity on Candida in
RDA similar to the reference peptides LL-37 and histatin-
5( Figure 2(b)). In order to determine possible antifungal
peptides of the rD5, overlapping peptides spanning the
D5-region were synthesized (Table 1). When HKH20 and
GKH17 were tested in RDA, a signiﬁcantly more potent
inhibitory activity on Candida, in comparison to LL-37, was
observed (Figure 2(c)). As shown, HKH20 possessed potent
antifungal activity (Figure 2(a)), and >80% of the Can-
dida cells were killed by 30μM HKH20 within 15minutes
(Figure 2(d)). In RDA, HKH20 displayed signiﬁcantly higher
inhibitory activity on Candida, when compared with LL-37
(Figures 2(b) and 2(c)). Finally, M. furfur w a st e s t e di na n
antifungal assay. The yeast cells were subjected to 10μMo r
30μM of LL-37, HKH20, or GKH17, and the results showed
that particularly HKH20 and GKH17 were antifungal at
10 and 30μM( Figure 2(e)). MIC values, deﬁned as the
concentration yielding at least 95% inhibition of fungal
growth, for HKH20 and GKH17 were determined to be
between 2.5–5μM and 5–10μM, respectively (Figure 2(f)).
3.3. The D5-Derived Peptide HKH20 Binds to the Surface of
Candida. To elucidate whether the peptide HKH20 interacts
with the fungal cell wall of Candida, HKH20, labeled with
the ﬂuorescent dye Texas Red, was incubated with the
fungal cells. As demonstrated by ﬂuorescence microscopy,
the peptide bound to the surface of Candida and the
binding were completely blocked by heparin, an anionic gly-
cosaminoglycan previously shown to block the antibacterial
activity of HKH20 [33]( Figure 2(g)).
3.4. Antifungal Eﬀects of D5-Derived Peptides and Struc-
tural Modiﬁcations for an Optimized Eﬀect at Physiological
Conditions. Hydrophobic tagging with W (Trp) amino acid
residues has previously been demonstrated to increase
antibacterial activity against various pathogens, such as
S. aureus and P. aeruginosa. Particularly, for short, highly
positively charged, and hydrophilic peptides, this facilitates
the design of potent AMPs that selectively bind microorgan-
isms over human cells [41–43]. Thus, the GKH17 peptide
was tagged with 3–5W residues at the C-terminal and
analysed for antifungal activity. As shown, the hydrophobic
modiﬁcation resulted in increased antifungal activity, which
was observed when not only in low salt conditions, but also
tested in physiological salt solution (0.15M NaCl) as well as
in the presence of human plasma and serum (20% and 50%)
(Figure 3).
3.5. Membrane-Disruptive Potency of GKH17 and End-Tagged
Variants. The membrane-disruptive potency for GKH17
and the end-tagged variant GKH17WWW were demon-
strated to be higher for ergosterol-containing liposomes
than for cholesterol-containing ones (Figure 4). This is in
line with the membrane-condensing eﬀect of cholesterol
[44–48], which opposes membrane insertion of peptides,
and the relatively smaller membrane condensation caused8 International Journal of Peptides
by ergosterol. Given this diﬀerence between cholesterol and
ergosterol, identiﬁcation of peptides which are selective
for ergosterol-containing membranes may represent a
means to achieve simultaneously antifungal and low-toxic
therapeutics.
4. Discussion
The D5 domain of HMWK is multifunctional and may par-
ticipate in cell binding [49], inhibit angiogenesis, prolifera-
tion,andmigrationofendothelialcells[50,51],andactasan
antibacterial agent [33]. The main result in the present study
is that cleavage products of HMWK also act as antifungal
peptides, paralleled by results showing that the D5 domain
of HMWK and related amino-acid sequences exert an anti-
fungal activity comparable with the well-known AMPs LL-
37 and histatin 5. Innate immune responses, including small
cationic peptides with antimicrobial activities, constitute the
ﬁrst line of defense and are crucial for rapid clearing of
microbial invaders. Numerous antimicrobial and antifun-
gal peptides have been identiﬁed to date, most of them
acting by membrane disruptive mechanisms. As mentioned
brieﬂy in the Introduction, biological eﬀects exerted by
AMPs include growth stimulus and angiogenesis, protease
inhibition, antiangiogenesis, and chemotaxis [52–54]. Con-
versely, cationic peptide motifs from proteins not previously
considered as AMPs have been shown to exert antimicrobial
activities. For example, complement C3 [55, 56], kininogen
[34, 57], heparin-binding protein [58], heparin-binding epi-
dermal growth factor and other growth factors [59], matrix
proteins such as laminin, ﬁbronectin and proline arginine-
rich and leucine-rich repeat protein (PRELP) [60], prions
[61], β2-glycoprotein [62], histidine-rich glycoprotein [10],
thrombin [63], and tissue factor pathway inhibitor [64]
may act either as holoproteins or smaller peptide derivatives
or fragments thereof and also exert antimicrobial activities
in vitro, and, in several cases, in vivo [10, 34, 57]. In
general, these ﬁndings are compatible with the observation
that consensus heparin-binding peptide sequences (Cardin
and Weintraub motifs) XBBBXXBX or XBBXBX (where X
represents hydrophobic or uncharged amino acids, and B
representsbasicaminoacids),representedbymultiplesofthe
motifs ARKKAAKA or AKKARA [65], are antibacterial [20]
and speciﬁcally interact with membranes [66].
The ﬁndings in this study therefore further underline
the multifunctionality of AMPs and illustrate that the
glycine- and histidine-rich part of D5, previously shown
to interact with heparin, may bind to negatively charged
fungal membranes, such as those of Candida and Malassezia
[67–70]. It is also notable that HKH20, derived from the
lysine- and histidine-rich region of D5, which comprises
consensus sequences for heparin binding [20, 65], binds
to the membrane of Candida, likely by interacting with
negatively charged molecules at the fungal cell wall [71].
Interestingly, HKH20 resembles the H-and K-rich AMP
histatin-5 (Table 1), an AMP known to mediate fungal
killing. It is also worth noting that the light chain of HMWK
is essential for the interaction of kininogen with the cell wall
of Candida [32].
As previously demonstrated, end-tagging by hydropho-
bic amino acid stretches is a facile and ﬂexible approach of
general applicability, by which AMP boosting, particularly
of linear cationic sequences, is obtained [72, 73]. The data
demonstrating that the hydrophobically modiﬁed GKH17
peptides show enhanced activity at physiological conditions,
and in presence of human plasma and serum are therefore
well in line with these previous data, suggesting that
increased hydrophobicity yields increased aﬃnity for fungal
membranes. Indeed, these data parallel the observations on
liposomes, demonstrating speciﬁcity for ergosterol (fungi-
like) liposomes compared with cholesterol (mammalian cell
mimicking) liposomes.
In previous reports, it was demonstrated that fragments
of HMWK are generated upon degradation with neutrophil
elastase as well as bacterial enzymes [74]. The observation
in the present study extend these previous ﬁndings and
demonstrate that cathepsin G, a major neutrophilic enzyme,
may also degrade HMWK, leading to release of AMPs
(Figure 1(c)). Considering these data as well as the ﬁnding
that PMNs may degrade HMWK and generate antifungal
activity (Figure 1(b)), it is tempting to speculate that during
ac u t a n e o u sCandida infection, neutrophils, recruited to the
siteofinfection[75,76],mayuponactivationreleasecathep-
sin G from azurophilic granules, leading to degradation of
HMWK, present in blood or connective tissues. The cleavage
products of HMWK can then act as antifungal AMPs and
inhibit fungal cells at the site of infection. However, further
investigations are clearly mandatory in order to further
deﬁne the generation of D5 peptides in response to fungal
infection.
In conclusion, we have shown that proteolysis of HMWK
generates fragments with antifungal activities. Amino-acid
sequences corresponding to D5-derived peptides exert anti-
fungal eﬀects, and, furthermore, the antifungal activity
may be enhanced by tagging with hydrophobic amino-acid
residues.
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